ELTX · Elicio Therapeutics, Inc. · Executive Compensation
$1.56
-0.07 (-4.29%)
At close · Nov 12
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We are currently facing substantial doubt about our ability to continue as a going concern, given our cash position and cash runway.”View the 10-Q filed Nov 5, 2026
Market Cap
$44.16M
Shares
28.31M
Volume · Nov 12
232.82K
Avg daily vol (3M)
320.42K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Robert Connelly | President, Chief Executive Officer, and Director | $1,887,660 |
| Preetam Shah | Ph.D., Chief Strategy and Financial Officer and Treasurer | $1,377,686 |
| Christopher Haqq | M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer | $1,078,176 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Robert Connelly | President, Chief Executive Officer, and Director | $2,036,441 |
| Christopher Haqq | M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer | $926,452 |
| Peter DeMuth | Chief Scientific Officer | $866,671 |
| Preetam Shah | Ph.D., Chief Strategy and Financial Officer and Treasurer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jay R. Venkatesan | former Chief Executive Officer, President, and Chairman of the Angion Board | $2,429,275 |
| Jennifer J. Rhodes | former Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary | $1,365,859 |
| Brian Piekos | former Chief Financial Officer and Treasurer | $878,755 |
| Robert Connelly | President, Chief Executive Officer, and Director | $678,300 |
| Christopher Haqq | M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer | $673,821 |
| Peter DeMuth | Chief Scientific Officer | $502,636 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jay R. Venkatesan | former Chief Executive Officer, President, and Chairman of the Angion Board | $1,518,849 |
| Robert Connelly | President, Chief Executive Officer, and Director | $1,256,040 |
| Christopher Haqq | M.D., Ph.D., Executive Vice President, Head of Research and Development and Chief Medical Officer | $1,162,356 |
| Jennifer J. Rhodes | former Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary | $773,653 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jay R. Venkatesan | M.D., President and Chief Executive Officer and Chairman of the Board | $2,539,199 |
| Itzhak D. Goldberg | M.D., Executive Chairman and Chief Scientific Officer | $1,247,881 |
| John F. Neylan | M.D., Executive Vice President, Chief Medical Officer and Head of Research | $1,232,513 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jay R. Venkatesan | M.D., President and Chief Executive Officer and Chairman of the Board | $1,394,398 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Preetam Shah, Ph.D., M.B.A. | Principal Accounting Officer | Appointed | 2025-03-24 |
| Preetam Shah, Ph.D., M.B.A. | Principal Financial Officer | Appointed | 2025-03-24 |
| Preetam Shah, Ph.D., M.B.A. | Chief Strategy and Financial Officer | Appointed | 2025-03-24 |
| Robert Connelly | Principal Accounting Officer and Principal Financial Officer | Appointed | 2024-10-17 |
| Brian Piekos | Chief Financial Officer and Treasurer | Resigned | 2024-08-30 |
| Annette Matthies, Ph.D. | Chief Business Officer | Terminated | 2023-10-12 |
| Assaf Segal | Board of Directors | Resigned | 2023-08-30 |
| Assaf Segal | Class II Director | Appointed | 2023-06-02 |
| Karen J. Wilson | Class II Director | Appointed | 2023-06-02 |
| Robert R. Ruffolo, Jr. | Class II Director | Appointed | 2023-06-02 |
| Allen R. Nissenson | Class I Director | Appointed | 2023-06-02 |
| Yekaterina (Katie) Chudnovsky | Class I Director | Appointed | 2023-06-02 |
| Jay R. Venkatesan | Class III Director | Appointed | 2023-06-02 |
| Julian Adams | Chair of the Board and Class III Director | Appointed | 2023-06-02 |
| Carol Ashe | Class III Director | Appointed | 2023-06-02 |
| Annette Matthies | Chief Business Officer | Appointed | 2023-06-02 |
| Christopher Haqq | Executive Vice President, Head of Research and Development and Chief Medical Officer | Appointed | 2023-06-02 |
| Peter DeMuth | Chief Scientific Officer | Appointed | 2023-06-02 |
| Robert Connelly | Chief Executive Officer, President and Class I Director | Appointed | 2023-06-02 |
| Brian Piekos | Chief Financial Officer | Appointed | 2023-06-02 |
| Daniel Geffken | Elicio's board of directors | Resigned | 2023-06-02 |
| Daphne Karydas | Elicio's board of directors | Resigned | 2023-06-02 |
| Gregory S. Curhan | Angion's Chief Financial Officer | Terminated | 2023-06-02 |
| Gilbert S. Omenn | member of Angion's board of directors | Resigned | 2023-06-02 |
| Itzhak D. Goldberg | member of Angion's board of directors | Resigned | 2023-06-02 |
Leadership
- Robert Connelly CEO, Chief Accounting Officer, Board Member
- Julian Adams Chairman
- Julian Adams, Ph.D. Chairman, Board Member
- Brian Piekos CFO
- Preetam Shah, Ph.D., M.B.A. CFO, Chief Accounting Officer
- Jennifer J. Rhodes General Counsel
- Allen R. Nissenson Board Member
- Allen R. Nissenson, M.D. Board Member
- Assaf Segal Board Member
- Carol Ashe Board Member
- Jay R. Venkatesan Board Member
- Jay R. Venkatesan, M.D. Board Member
- Karen J. Wilson Board Member
- Robert R. Ruffolo Board Member
- Robert R. Ruffolo, Jr. Board Member
- Robert R. Ruffolo, Jr., Ph.D., FCPP Board Member
- Yekaterina (Katie) Chudnovsky Board Member
Key facts
CIK
1601485
CUSIP
28657F103
13F (30d)
44 filings
43 filers
Visit website
Investor relations